Key Points:
- Moderna struck a massive settlement with Genevant Sciences and Arbutus Biopharma.
- The legal fight involved the delivery technology inside the Spikevax vaccine.
- Moderna will pay almost one billion dollars upfront in July 2026.
- A pending court appeal will decide the fate of the remaining money.
Moderna finally ended a massive legal battle over the technology behind its famous COVID-19 vaccine. The drugmaker agreed to a global settlement worth up to $2.25 billion with Genevant Sciences and Arbutus Biopharma. Genevant operates as a subsidiary of Roivant Sciences.
The dispute centered around lipid nanoparticle technology, which scientists call LNP. This technology acts as a tiny, protective bubble. It wraps around fragile mRNA molecules so they can safely enter human cells. Without this crucial delivery system, the Spikevax vaccine simply would not work.
Genevant and Arbutus claimed they owned the original patents for this LNP method. They accused Moderna of using their intellectual property without asking for permission. Tuesday’s agreement officially resolves all international and domestic lawsuits between the rival companies.
Under the new deal, Moderna structured its penalty into two distinct parts. First, the company will hand over a $950 million upfront cash payment. The pharmaceutical giant scheduled this initial payment for July 2026.
The remaining $1.3 billion remains up in the air. Moderna will only pay this second amount if a pending court appeal fails. Moderna argues that a unique law shields the company from patent liability for vaccine doses it sold directly to the federal government.
As part of the truce, Genevant officially grants Moderna a global license to use the LNP technology for future infectious disease vaccines. This clears a major legal hurdle for Moderna as the company develops new mRNA treatments.
Wall Street loved the news. Investors quickly bought up stock in all the involved companies during extended trading sessions. Moderna saw its shares jump more than 10 percent. Arbutus enjoyed an 11 percent spike, and Roivant shares climbed higher as well.
